文献速递胸部肿瘤

PD-1通路抑制剂在合并自身免疫病的NSCLC患者中的安全性

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
PubMed 文献 · J Clin Oncol · 2018-05-10

该多中心回顾性研究纳入56例合并自身免疫病(AID)的非小细胞肺癌(NSCLC)患者,接受PD-1或PD-L1抑制剂单药治疗。55%出现AID flare和/或免疫相关不良事件(irAE),AID加重见于23%的患者,irAE发生率为38%,多数为1-2级,14%因irAE永久停药,免疫治疗客观缓解率为22%。

要点

  • 合并AID的NSCLC患者中AID加重见于少数(23%),多为可控。
  • irAE发生率38%,与排除AID患者的临床试验报告率相似。
  • 因irAE永久停药者占14%,不良事件总体可管理。

核心结论

  • 在合并AID的NSCLC患者中,PD-(L)1抑制剂治疗时AID加重发生于少数患者,irAE发生率与排除AID患者的临床试验相似,不良事件总体可管理且较少导致永久停药。

研究设计与样本

  • 多中心回顾性研究,收集合并AID且接受PD-1或PD-L1抑制剂单药治疗的NSCLC患者的临床病理数据,共识别56例患者。
  • 符合条件的AID包括风湿性、神经性、内分泌、胃肠道及皮肤疾病等,但不限于此。

主要发现

  • 55%的患者出现AID flare和/或irAE;AID加重见于13例(占全队列23%),其中4例需全身糖皮质激素。
  • irAE发生于21例(38%),其中74%为1或2级、26%为3或4级,8例需糖皮质激素处理。
  • 8例(14%)因irAE永久停用PD-(L)1治疗;该人群免疫治疗总体缓解率为22%。
  • 治疗开始时18%的患者有活动性AID症状,20%正因AID接受免疫调节药物。

临床怎么用

  • 对合并AID的NSCLC患者,PD-(L)1抑制剂并非绝对禁忌,可在评估后使用并监测AID flare与irAE。
  • 多数不良事件为轻中度且可管理,但需警惕少数需激素处理或导致永久停药的事件。

局限性

  • 为回顾性研究,样本量56例,未设对照,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all patients with advanced non-small-cell lung cancer (NSCLC), the large number of patients with NSCLC and concurrent autoimmune disease (AID) have been universally excluded from immunotherapy clinical trials. Therefore, the safety of PD-1 and PD-ligand 1 (PD-L1) inhibitors in patients with NSCLC and underlying AID is currently unknown. Methods As part of a multi-institutional effort, we retrospectively collected clinicopathologic data from patients with NSCLC and a history of AID who received monotherapy with either a PD-1 or a PD-L1 (herein referred to as PD-[L]1) inhibitor. Qualifying AIDs included but were not limited to: rheumatologic, neurologic, endocrine, GI, and dermatologic conditions. Results We identified 56 patients with NSCLC and an AID who received a PD-(L)1 inhibitor. At the time of treatment initiation, 18% of patients had active AID symptoms and 20% were receiving immunomodulatory agents for their AID. A total of 55% of patients developed an AID flare and/or an immune-related adverse event (irAE). Exacerbation of the AID occurred in 13 patients (23% of the whole cohort), four of whom required systemic corticosteroids. Immune-related adverse events occurred in 21 patients (38%). Among irAEs, 74% were grade 1 or 2 and 26% were grade 3 or 4; eight patients required corticosteroids for irAE management. PD-(L)1 therapy was permanently discontinued in eight patients (14%) because of irAEs. The overall response rate to immunotherapy in this population was 22%. Conclusion In patients with NSCLC with AID treated with a PD-(L)1 inhibitor, exacerbation of AID occurred in a minority of patients. The incidence of irAEs was similar to reported rates in clinical trials where patients with AID were excluded. Adverse events were generally manageable and infrequently led to permanent discontinuation of immunotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leonardi GC, Gainor JF, Altan M, et al. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018. PMID: 29746230. doi:10.1200/JCO.2017.77.0305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。